Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors

NCT02527434 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02527434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02527434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 2, 2015
Completion date
March 28, 2023
Enrollment
64 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma, triple-negative breast cancer, urothelial bladder cancer